8-K Announcements
6Material company update
Jun 4, 2026·SEC
Material company update
Dec 16, 2025·SEC
Material company update
Oct 8, 2025·SEC
Biomerica, Inc.(BMRA)Earnings, Financials & Key Ratios
BMRA•NASDAQ
$1.75
Price updated Jun 27, 2026
AboutBiomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Show more
- Revenue$5M-1.9%
- EBITDA-$5M+21.0%
- Net Income-$5M+16.8%
- EPS (Diluted)-2.16-500.0%
- Gross Margin9.38%-16.9%
- EBITDA Margin-89.19%+19.4%
- Operating Margin-96.72%+17.7%
- Net Margin-93.64%+15.2%
- ROE-92.99%-42.4%
BMRA Price & Volume
Biomerica, Inc. (BMRA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Revenue Contraction Threatens Operational Liquidity Runway
Investment Thesis • Updated 2026Q3
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Capital exhaustion and liquidity
"Biomerica faces a critical inflection point as its legacy diagnostic business continues to erode, evidenced by a revenue decline to $987.0K in 2026Q3. The company's strategic pivot toward the InFoods platform remains unproven, with operating margins collapsing to -131.5% and cash reserves dwindling to $1.3 million. Investors should remain cautious as the firm's inability to achieve positive free cash flow, which reached -$1.3 million in 2026Q3, suggests significant ongoing liquidity risk."
Verdict Logic
the company's net margin of -132.9% and the rapid depletion of cash reserves to $1.3 million indicate a high probability of future capital dilution or liquidity distress.
BMRA Growth Metrics
Biomerica, Inc. (BMRA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.68%
5 Years-4.52%
3 Years-34.47%
TTM-14.07%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM20.73%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-266.98%
Return on Capital
10 Years-47.61%
5 Years-65.02%
3 Years-74.15%
Last Year-91.28%
Peers Comparison
Key metrics vs top competitors for Biomerica, Inc. (BMRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.75 | $5.41M | -0.81 | -1.92% | -93.64% | -92.99% | — | |
| $3.06 | $3.42M | -0.09 | -84.1% | -6753.69% | -164.92% | — | |
| $13.79 | $938.85M | -0.83 | -1.89% | -45.57% | -56.31% | — | |
| $4.46 | $320.97M | -4.74 | -38.1% | -61.93% | -15.09% | — | |
| $76.01 | $16.97B | 30.53 | 1.74% | 13.18% | 11.01% | — | |
| $300.79 | $8.12B | 10.79 | 0.65% | 6.52% | 2.4% | — |
Compare BMRA vs Peers
Biomerica, Inc. (BMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMRA SEC Filings & Documents
Biomerica, Inc. (BMRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BMRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMRA Frequently Asked Questions
Biomerica, Inc. (BMRA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Biomerica, Inc.'s revenue?
Biomerica, Inc. (BMRA) reported $4.6M in revenue for fiscal year 2025. This represents a 52% decrease from $9.5M in 1996.
How fast is Biomerica, Inc. growing?
Biomerica, Inc. (BMRA) saw revenue decline by 1.9% over the past year.
Is BMRA profitable?
Biomerica, Inc. (BMRA) reported a net loss of $3.9M for fiscal year 2025.
Dividend & Returns
What is BMRA's return on equity?
Biomerica, Inc. (BMRA) has a return on equity (ROE) of -93.0%. Negative ROE indicates the company is unprofitable.
What is Biomerica, Inc.'s free cash flow?
Biomerica, Inc. (BMRA) had negative free cash flow of $3.8M in fiscal year 2025, likely due to heavy capital investments.